Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed Nov 14, 2024 · 10-Q · 45 days after period end · 0001410578-24-002000
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.71M | -$1.23M | -$6.86M | -$5.34M |
| EPS Diluted | -$0.51 | -$0.45 | -$0.19 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end
